Indium (In-111) Chloride Curium (Indium (111in))

After intravenous injection, Indium‑111 binds to plasma proteins and accumulates in tissues with increased vascular permeability or active immune cell recruitment. The radionuclide emits gamma photons that are captured by a gamma camera, producing detailed images of the targeted area such as tumors, inflamed tissue, or infection sites.

The administered activity of Indium (In-111) Chloride Curium is determined by the prescribing physician based on the specific diagnostic indication, patient weight, and imaging protocol. Dosage is individualized and should follow the relevant nuclear medicine guidelines and local regulatory requirements.

Safety data for Indium (In-111) Chloride Curium in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential fetal or infant radiation exposure. If administered, a risk‑benefit assessment should be performed by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed) and assist with import documentation.

Indium‑111 offers a longer half‑life (≈2.8 days) and gamma emission energies suitable for high‑resolution imaging, making it advantageous for delayed imaging and leukocyte labeling. Compared with technetium‑99m agents, it provides extended imaging windows but involves higher radiation dose, requiring careful patient selection.

The product should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It must be kept in its original container until use and handled by trained personnel using appropriate radiation safety measures.

Indium (In-111) Chloride Curium is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The injection is performed under aseptic conditions, followed by the appropriate imaging protocol.

Serious risks include severe allergic reactions (anaphylaxis), radiation‑induced skin injury at the injection site, significant hypotension, arrhythmias, and bone‑marrow suppression with high cumulative doses. Immediate medical attention is required if any severe reaction occurs.

Patients with known hypersensitivity to indium compounds, those who are pregnant or breastfeeding (unless essential), individuals with severe renal impairment without appropriate monitoring, and patients who have recently received other radiopharmaceuticals that could cause excessive radiation exposure should avoid this agent.